Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled multicenter study of WS016 in patients with hyperkalemia
CTR20244172Phase 3Active
- Sponsor
- Waterstone Pharmaceuticals
- Start
- Dec 2024
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of WS016 in hyperkalemia, sponsored by Waterstone Pharmaceuticals. Started Dec 2024; status: active.
02
Drugs
WS016
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on CTR20244172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244172.